Literature DB >> 31340393

Circulating Serum Myonectin Levels in Obesity and Type 2 Diabetes Mellitus.

Zhu Li1, Yan-Ling Yang2, Yan-Juan Zhu1, Chen-Guang Li1, Yun-Zhao Tang1, Chang-Lin Ni1, Li-Ming Chen1, Wen-Yan Niu1,3.   

Abstract

OBJECTIVE: Myonectin is one of the myokines and has gained interest as a potential new strategy to combat obesity and its associated disorders, such as type 2 diabetes mellitus (T2DM).The objective of this study was to investigate circulating serum myonectin levels in nondiabetes and T2DM and elucidate possible relationships between serum myonectin levels and metabolic parameters in patients with T2DM.
DESIGN: A total of 362 Chinese patients with T2DM and 100 age- and sex-matched healthy controls were recruited in this study. Clinical characteristics, blood biochemistry, and circulating myonectin levels were measured by enzyme-linked immunosorbent assay.
RESULTS: Circulating myonectin levels were significantly decreased in T2DM compared with controls. Obese nondiabetic controls had significantly lower serum myonectin levels compared with lean nondiabetic controls. In diabetic patients, serum myonectin concentrations were significantly negatively correlated with body mass index (BMI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), hemoglobin A1c (HbA1c), fasting insulin (Fins), the homeostatic model assessment of insulin resistance (HOMA-IR), visceral fat area, and subcutaneous fat area. After adjusting for covariates, multivariate stepwise regression analysis demonstrated that BMI, LDL-C, TG, HOMA-IR, and visceral fat were the main independent predictors of low serum myonectin concentrations.
CONCLUSIONS: Circulating myonectin levels were decreased in T2DM patients and in obese subjects. Moreover, serum myonectin levels were correlated with metabolic markers of T2DM. These data suggest that myonectin may be a useful marker in predicting the development of obesity and T2DM. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31340393     DOI: 10.1055/a-0896-8548

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  5 in total

1.  Plasma Complement C1q/tumor necrosis factor-related protein 15 concentration is associated with polycystic ovary syndrome.

Authors:  Akram Vatannejad; Reza Fadaei; Fouzieh Salimi; Fatima Zahraa Fouani; Behnam Habibi; Somayeh Shapourizadeh; Samira Eivazi; Sadegh Eivazi; Asie Sadeghi; Nariman Moradi
Journal:  PLoS One       Date:  2022-06-14       Impact factor: 3.752

Review 2.  Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients-The Debate Is Still Open.

Authors:  Jagoda Kruszewska; Hanna Laudy-Wiaderny; Michał Kunicki
Journal:  Int J Environ Res Public Health       Date:  2022-02-13       Impact factor: 3.390

Review 3.  Mechanisms by Which Skeletal Muscle Myokines Ameliorate Insulin Resistance.

Authors:  Rekha Balakrishnan; Debbie C Thurmond
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

Review 4.  Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.

Authors:  Daniel N Srole; Tomas Ganz
Journal:  J Cell Physiol       Date:  2020-12-28       Impact factor: 6.513

5.  Male-specific Association between Iron and Lipid Metabolism Changes and Erythroferrone after Hepatitis C Virus Eradication.

Authors:  Shinjiro Inomata; Daisuke Morihara; Akira Anan; Eri Yamauchi; Ryo Yamauchi; Kazuhide Takata; Takashi Tanaka; Keiji Yokoyama; Yasuaki Takeyama; Makoto Irie; Satoshi Shakado; Tetsuro Sohda; Shotaro Sakisaka; Fumihito Hirai
Journal:  Intern Med       Date:  2021-08-24       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.